Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer

Inclusion Criteria: * Histologic or cytologic diagnosis of adenocarcinoma of the pancreas that is locally advanced \& not amenable to resection with curative intent. * Must not have received prior systemic therapy for locally advanced disease. * ECOG performance status must be 0-2. * Adequate hepatic, renal \& bone marrow function. * Radiographic evidence of disease is required. * Life expectancy \> 12 weeks. Exclusion Criteria: * Prior treatment with Capecitabine \& other EGFR inhibitor. * Patients with GI tract disease resulting in an inability to take oral medications. * Significant GI disorders with diarrhea as a major symptom. * Uncontrolled intercurrent illness including active infection,symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias now well controlled with medication, myocardial infarction within the previous 6 months, psychiatric illness/social situations that would limit compliance with study requirements. * Patients with metastases. * Patients who have had chemotherapy. * Patients may not be receiving any other investigational agents, or have participated in any investigational drug study. * Extensive symptomatic fibrosis of the lungs. * Females who are pregnant or lactating. * History of any other malignancy in the last 2 years, except prior history of in situ cancer, basal or squamous cell skin cancer are eligible. * Known DPD deficiency. * Receiving therapeutic doses of Coumarin-derivative anticoagulant therapy. Patients requiring anticoagulation who may be safely switched to LMWH are eligible.